Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Entry into a Material Definitive Agreement
12 Mar 24
8-K
Other Events
29 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
Other Events
27 Sep 23
8-K
Other Events
25 Aug 23
NT 10-Q
Notice of late quarterly filing
25 Aug 23
8-K
Other Events
30 Jun 23
8-K
Other Events
30 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
8-K
Other Events
10 May 23
NT 10-K
Notice of late annual filing
3 Apr 23
8-K
Other Events
24 Mar 23
8-K
Other Events
24 Feb 23
8-K
Termination of a Material Definitive Agreement
25 Jan 23
8-K
Entry into a Material Definitive Agreement
17 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Dec 22
25-NSE
Exchange delisting
21 Dec 22
8-K
Departure of Directors or Certain Officers
2 Dec 22
8-K
Departure of Directors or Certain Officers
23 Nov 22
NT 10-Q
Notice of late quarterly filing
15 Nov 22
8-K
Entry into a Material Definitive Agreement
8 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Oct 22
8-K
Bankruptcy or Receivership
24 Oct 22
8-K
Entry into a Material Definitive Agreement
7 Oct 22
8-K
Other Events
27 Sep 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
12 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
20 May 22
10-Q
2022 Q1
Quarterly report
16 May 22
8-K
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
16 May 22
DEF 14A
Definitive proxy
22 Apr 22
8-K
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
4 Apr 22
10-K
2021 FY
Annual report
24 Mar 22
8-K
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
24 Mar 22
S-8
Registration of securities for employees
14 Jan 22
8-K
PhaseBio Provides Pemziviptadil (PB1046) Program Update
21 Dec 21
Latest ownership filings
4
den Broek Richard van
19 May 23
4
Clay Thorp
19 May 23
4
William D. Humphries
19 May 23
4
EDMUND HARRIGAN
19 May 23
4
Alex Sapir
19 May 23
4
Caroline M Loewy
19 May 23
4
Nancy J Hutson
19 May 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Rock Springs Capital Management LP
14 Feb 23
SC 13G/A
Avidity Partners Management LP
14 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13D/A
NEW ENTERPRISE ASSOCIATES 13 LP
4 Nov 22
4
FOREST BASKETT
26 Oct 22
SC 13G/A
MAI Capital Management
19 Jul 22
4/A
William D. Humphries
10 Jun 22
4
Susan Elizabeth Arnold
24 May 22
4
Jonathan P Mow
24 May 22
4
Glen Burkhardt
24 May 22
4
Kristopher Hanson
24 May 22
4
Jonathan Birchall
24 May 22
4
John P Sharp
24 May 22
4/A
Nancy J Hutson
20 May 22
4
William D. Humphries
20 May 22
4
Clay Thorp
20 May 22
4
Nancy J Hutson
20 May 22
4
Alex Sapir
20 May 22
4
Caroline M Loewy
20 May 22
4
EDMUND HARRIGAN
20 May 22
4
den Broek Richard van
20 May 22
4
John P Sharp
28 Feb 22
4
Glen Burkhardt
28 Feb 22
4
Jonathan Birchall
28 Feb 22
4
John Sang Lee
28 Feb 22
4
Susan Elizabeth Arnold
28 Feb 22
4
Kristopher Hanson
28 Feb 22
4
Jonathan P Mow
28 Feb 22
SC 13G/A
Rock Springs Capital Management LP
15 Feb 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 22
SC 13G/A
Avidity Partners Management LP
14 Feb 22
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 22